Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 52, Issue 2, 2011, Pages 198-202

  Barshop, Nicole J ^a   Capparelli, Edmund V ^a   Sirlin, Claude B ^b   Schwimmer, Jeffrey B ^a   Lavine, Joel E ^a  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acetaminophen; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; pediatrics; pharmacokinetics; UDP glucuronyltransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; APAP G; ASPARTATE AMINOTRANSFERASE; DEXTROMETHORPHAN; DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; PARACETAMOL; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; GROUPS BY AGE AND SEX; HUMAN; LIVER FUNCTION; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE;

ACETAMINOPHEN; ADOLESCENT; CASE-CONTROL STUDIES; CHILD; FATTY LIVER; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MALE; STATISTICS, NONPARAMETRIC;

EID: 79951669908     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181f9b3a0     Document Type: Article

References (23)

1. Barshop NJ, Sirlin CB, Schwimmer JB, et al. Review article: epidemiology, pathogenesis and potential treatments of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2008;28: 13-24. (Pubitemid 351782810)
2. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388-93. (Pubitemid 46393782)
3. Leclercq I, Horsmans Y, Desager JP, et al. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998;28:410-6. (Pubitemid 28133544)
4. Gomez-Lechon MJ, Jover R, Donato MT. Cytochrome P450 and steatosis. Curr Drug Metab 2009;10:692-9.
5. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39:215-31.
6. Chun LJ, Tong MJ, Busuttil RW, et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009;43:342-9.
7. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005;12:133-41. (Pubitemid 40516030)
8. Osabe M, Sugatani J, Fukuyama T, et al. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator- activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab Dispos 2008;36:294-302. (Pubitemid 351185741)
9. Alam SN, Roberts RJ, Fischer LJ. Age-related differences in salicyla-mide and acetaminophen conjugation in man. J Pediatr 1977;90:130-5. (Pubitemid 8015655)
10. Al-Obaidy SS, Li Wan Po A, McKiernan PJ, et al. Assay of paracetamol and its metabolites in urine, plasma and saliva of children with chronic liver disease. J Pharm Biomed Anal 1995;13:1033-9.
11. Cummings AJ, King ML, Martin BK. A kinetic study of drug elimination: the excretion of paracetamol and its metabolites in man. Br J Pharmacol Chemother 1967;29:150-7.
12. van der Marel CD, Anderson BJ, van Lingen RA, et al. Paracetamol and metabolite pharmacokinetics in infants. Eur J Clin Pharmacol 2003; 59:243-51. (Pubitemid 36995133)
13. Raucy JL, Lasker JM, Kraner JC, et al. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol 1991;39:275-80.
14. Dong ZG, Hong JY, Ma QA, et al. Mechanism of induction of cytochrome P-450ac (P-450j) in chemically induced and spontaneously diabetic rats. Arch Biochem Biophys 1988;263:29-35.
15. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology (Baltimore) 2003;38:428-35. (Pubitemid 36919864)
16. Chalasani N, Gorski JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (Baltimore) 2003;37:544-50. (Pubitemid 36258775)
17. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore) 1998;27:128-33. (Pubitemid 28041545)
18. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645-53. (Pubitemid 26404230)
19. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatol-ogy (Baltimore) 2005;42:473-80. (Pubitemid 41061101)
20. Donthamsetty S, Bhave VS, Mitra MS, et al. Nonalcoholic steatohe-patitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol Appl Pharmacol 2008;230:327-37.
21. Al-Obaidy SS, McKiernan PJ, Li Wan Po A, et al. Metabolism of paracetamol in children with chronic liver disease. Eur J Clin Pharmacol 1996;50:69-76. (Pubitemid 26141507)
22. Evans WE, Relling MV, Petros WP, et al. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989;45:568-73. (Pubitemid 19155038)
23. Streetman DS, Bleakley JF, Kim JS, et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltrans-ferase-2, and xanthine oxidase with the ''Cooperstown cocktail.'' Clin Pharmacol Ther 2000;68:375-83.